MedTrace Logo

The Safety and Efficacy of Fibrinolysis in Patients With an Indwelling Pleural Catheter for Multi-loculated Malignant Pleural Effusion.

NCT03678090 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2020-03-05

No results posted yet for this study

Summary

The safety and efficacy of fibrinolysis in patients with an indwelling pleural catheter for multi-loculated malignant pleural effusion.

Conditions

  • Pleural Effusion
  • Cancer, Lung

Interventions

DRUG

tPA standard dosage

Tissue plasminogen activator 25mg dosage

DRUG

tPA low dosage

Tissue plasminogen activator 2.5mg

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Mark Godfrey, MD · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-12-01
Primary Completion
2020-02-28
Completion
2020-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03678090 on ClinicalTrials.gov